After more than 2000 years, the Scientific Community has widely recognized the central role of gut microbiota on people’s health. An altered microbiota can affect various organs and functions (skin, CNS, metabolism, immunity) and some probiotics can balance and modulate it with positive effects.
On this basis, Cerbios-Pharma SA developed and tested some finished formulations where its own proprietary probiotic strain Enterocooccus lactis SF68® (formerly Enterococcus faecium SF68®) is mixed with other innovative functional ingredients, carefully selected by our R&D Department. Their synergic effect brings to a multilevel management of different conditions.
IBS (Irritable Bowel Syndrome) is one of most common GI disease (constipation or diarrhea, visceral pain, swelling) and represents an unmet medical need, due to unsatisfactory treatments on the market. Some symptoms are common with IBD diseases. Dysbiosis is often associated to IBS. Probiotics can be indicated for prevention and management of IBS. Postbiotics like butyrate (SCFA, Short Chain Fatty Acids, like Butyrate) reduce inflammatory status and folic acid (here as L- Methylfolate, the biological active form) have a synergic effect on symptoms.
Product: E. lactis SF68®, Butyrate and L- Methylfolate.
Presentation: 30 caps.
Scientific evidence: Preclinical evidence demonstrating efficacy on prevention and management of IBS symptoms. Clinical trial planned by 2023. Patent pending.
Status: Food for Special Medical Purposes (with a full Technical Dossier).